Cargando…
A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework
A mechanistic, multistate, mathematical model of inflammatory bowel disease (IBD) was developed by including key biological mechanisms in blood and gut, including cell differentiation, cytokine production, and clinical biomarkers. The model structure is consistent between healthy volunteers and IBD...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877855/ https://www.ncbi.nlm.nih.gov/pubmed/32822108 http://dx.doi.org/10.1111/cts.12849 |
_version_ | 1783650251752603648 |
---|---|
author | Rogers, Katharine V. Martin, Steven W. Bhattacharya, Indranil Singh, Ravi Shankar Prasad Nayak, Satyaprakash |
author_facet | Rogers, Katharine V. Martin, Steven W. Bhattacharya, Indranil Singh, Ravi Shankar Prasad Nayak, Satyaprakash |
author_sort | Rogers, Katharine V. |
collection | PubMed |
description | A mechanistic, multistate, mathematical model of inflammatory bowel disease (IBD) was developed by including key biological mechanisms in blood and gut, including cell differentiation, cytokine production, and clinical biomarkers. The model structure is consistent between healthy volunteers and IBD disease phenotype, with 24 parameters changed between diseases. Modular nature of the model allows for easy incorporation of new mechanisms or modification of existing interactions. Model simulations for steady‐state levels of proteins and cells in the blood and gut using a population approach are consistent with published data. By simulating the response of two clinical biomarkers, C‐reactive protein and fecal calprotectin, to parameter perturbations, the model explores hypotheses for possible treatment mechanisms. With additional experimental validation and addition of drug treatments, the model provides a platform to test hypothesis on treatment effects in IBD. |
format | Online Article Text |
id | pubmed-7877855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78778552021-02-18 A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework Rogers, Katharine V. Martin, Steven W. Bhattacharya, Indranil Singh, Ravi Shankar Prasad Nayak, Satyaprakash Clin Transl Sci Research A mechanistic, multistate, mathematical model of inflammatory bowel disease (IBD) was developed by including key biological mechanisms in blood and gut, including cell differentiation, cytokine production, and clinical biomarkers. The model structure is consistent between healthy volunteers and IBD disease phenotype, with 24 parameters changed between diseases. Modular nature of the model allows for easy incorporation of new mechanisms or modification of existing interactions. Model simulations for steady‐state levels of proteins and cells in the blood and gut using a population approach are consistent with published data. By simulating the response of two clinical biomarkers, C‐reactive protein and fecal calprotectin, to parameter perturbations, the model explores hypotheses for possible treatment mechanisms. With additional experimental validation and addition of drug treatments, the model provides a platform to test hypothesis on treatment effects in IBD. John Wiley and Sons Inc. 2020-08-21 2021-01 /pmc/articles/PMC7877855/ /pubmed/32822108 http://dx.doi.org/10.1111/cts.12849 Text en © 2020 Pfizer Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Rogers, Katharine V. Martin, Steven W. Bhattacharya, Indranil Singh, Ravi Shankar Prasad Nayak, Satyaprakash A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework |
title | A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework |
title_full | A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework |
title_fullStr | A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework |
title_full_unstemmed | A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework |
title_short | A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework |
title_sort | dynamic quantitative systems pharmacology model of inflammatory bowel disease: part 1 – model framework |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877855/ https://www.ncbi.nlm.nih.gov/pubmed/32822108 http://dx.doi.org/10.1111/cts.12849 |
work_keys_str_mv | AT rogerskatharinev adynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework AT martinstevenw adynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework AT bhattacharyaindranil adynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework AT singhravishankarprasad adynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework AT nayaksatyaprakash adynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework AT rogerskatharinev dynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework AT martinstevenw dynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework AT bhattacharyaindranil dynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework AT singhravishankarprasad dynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework AT nayaksatyaprakash dynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework |